Biovie (BIVI) Other Accumulated Expenses (2021 - 2023)
Biovie (BIVI) posted Other Accumulated Expenses of $48385.0 for Q2 2023, down 75.0% sequentially from $193542.0 in Q1 2023, and down 96.29% YoY from $1.3 million in Q2 2022.
Biovie (BIVI) Other Accumulated Expenses (2021 - 2023) Analysis & Trends
Biovie has reported Other Accumulated Expenses for 3 years, with the latest figure at $48385.0 in Q2 2023.
- Quarterly Other Accumulated Expenses fell 96.29% year-over-year to $48385.0 in Q2 2023, while the trailing twelve-month figure through Jun 2023 was $48385.0 (down 96.29% YoY) and the FY2023 annual result came in at $48385.0, down 96.29% from the prior year.
- Other Accumulated Expenses eased to $48385.0 in Q2 2023 per BIVI's latest filing, from $193542.0 in the prior quarter.
- Over five years, Other Accumulated Expenses peaked at $1.3 million in Q2 2022 and troughed at $48385.0 in Q2 2023.
- A 3-year average of $513909.9 and a median of $532239.5 in 2021 frame the typical range for Other Accumulated Expenses.
- The sharpest annual moves came in 2022 and 2023: Other Accumulated Expenses fell 16.67% in 2022, then slumped 96.29% in 2023.
- Over 3 years, Other Accumulated Expenses stood at $580625.0 in 2021, then slumped by 41.67% to $338698.0 in 2022, then plunged by 85.71% to $48385.0 in 2023.
- According to Business Quant data, Other Accumulated Expenses over the past three periods registered $48385.0, $193542.0, and $338698.0 for Q2 2023, Q1 2023, and Q4 2022 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Biovie | 14.17 Mn | 14.17 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 48,385.00 |
| Mar 31, 2023 | 193,542.00 |
| Dec 31, 2022 | 338,698.00 |
| Sep 30, 2022 | 483,854.00 |
| Jun 30, 2022 | 1.30 Mn |
| Mar 31, 2022 | 580,625.00 |
| Dec 31, 2021 | 580,625.00 |
| Sep 30, 2021 | 580,625.00 |